Google's Verily Makes Clinical Trials Pitch With Big Pharma Pacts
Verily has kept a low profile since it was set up in 2015 but deals with Novartis, Otsuka, Pfizer and Sanofi reveal the data management giant's ambitions to become a major player in the lucrative clinical studies space.
You may also be interested in...
Lilly licenses non-opioid pain candidate from Centrexion. China’s Hansoh gets rights to inibelizumab from AstraZeneca spinout Viela for lead indication neuromyelitis optica as well as other autoimmune and blood cancer indications.
The Swiss major has been showcasing its Nerve Live data analytics platform, where staff stationed at its SENSE operations center in Basel can monitor 500 or so clinical studies to predict - and stop - potential delays.
Novartis’s cancer drug has now been filed for multiple sclerosis in the US, armed with a priority review, and in Europe.